INBX as reported
Inhibrx Biosciences, Inc. reported $1.3M of revenue over the trailing twelve months. 7 reported series are charted on this page, each one as filed.
$1.3M
Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied
- Net Income
- −$130M
Net Income · −108% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$132M
Free Cash Flow · −22% year on year · trailing twelve months to Q1 2026
- EPS
- −$8.39
EPS · −107% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.3M | n/a | Q4 2025 |
| Net Income | −$130M | −108% | Q1 2026 |
| EPS | −$8.39 | −107% | Q1 2026 |
| ROE | −448% | n/a | Q1 2026 |
| ROA | −83% | n/a | Q1 2026 |
| ROIC | 848% | n/a | Q1 2026 |
| Free Cash Flow | −$132M | −22% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Inhibrx Biosciences, Inc. (INBX) - Revenue & ProfitRevenue & ProfitInhibrx Biosciences, Inc. (INBX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com